SEC Form 4 · accession 0001686266-17-000002
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip R Harper
10% Owner
Period of report
Mar 22, 2017
Accepted (ET)
Mar 27, 2017 · 2:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 22, 2017 | P | 1,000,000 | $1.79 | A | 4,786,682 | D | |
| Common Stock | Mar 23, 2017 | P | 4,705 | $1.60 | A | 4,791,387 | D | |
| Common Stock | Mar 24, 2017 | P | 53,826 | $1.60 | A | 4,845,213 | D | |
| Common StockF2 | holding | — | — | — | 220,000 | I | By wife |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.80, inclusive. The reporting person undertakes to provide to the issuer, its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F2The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.